In recent years, JUQ-097 has appeared in various online platforms, including forums and encrypted messaging apps . This has led some to believe that JUQ-097 might be used as a covert communication channel or a marker for clandestine activities .
| # | Citation | Link | |---|----------|------| | 1 | “NOP‑Receptor Antagonism Reduces Alcohol‑Seeking in Rodents.” Neuropsychopharmacology 2022; 47:123‑135. | https://doi.org/10.1038/npp.2021.200 | | 2 | Janssen Internal Clinical Study Report – Phase Ib JUQ-097
Once I have more context, I'll do my best to help you craft a well-structured and informative essay. In recent years, JUQ-097 has appeared in various
| Area | Open Question | Planned/Proposed Study | |------|---------------|------------------------| | | Does NOP antagonism reduce opioid or stimulant relapse? | Phase IIb exploratory arm in opioid‑use disorder (OUD) slated for 2027. | | Neuroimaging biomarkers | Which brain circuits show occupancy‑linked changes? | PET ligand (NOP‑specific) study using [¹⁸F]‑JNJ‑54175446, recruiting 30 AUD patients (2026). | | Precision medicine | Are there genetic polymorphisms (OPRL1) that predict response? | Genome‑wide association sub‑analysis of Phase II data. | | Long‑term safety | Effects beyond 12 months, especially on mood and cognition? | Open‑label extension (OLE) up to 24 months (ongoing). | | Combination with Naltrexone | Additive or synergistic anti‑craving? | Small‑scale crossover trial (n = 40) planned for late 2026. | | https://doi
Some speculate that JUQ-097 could be a: